{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:19:35Z","timestamp":1789129175122,"version":"build-2803163510"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Survival rates exceeding 85% are now achieved for most children diagnosed with B-cell precursor acute lymphoblastic leukemia (BCP-ALL), the most common subtype of childhood ALL. Advances in the understanding of disease biology, the identification of robust prognostic factors, and the implementation of risk-adapted treatment protocols have enabled increasingly personalized therapeutic approaches. The integration of RNA sequencing into routine diagnostics has further refined subtype classification and facilitated the detection of cryptic rearrangements and pathogenic variants. Despite these improvements, a subset of patients still experience relapse\u2014even those with favorable clinical and cytogenetic features as well as early clearance of residual disease. This overview underscores persistent gaps in current risk-stratification strategies; an important consideration, particularly for children assigned to low-risk groups who consequently receive reduced-intensity therapy. In this review, we synthesize current evidence on the diagnostic transcriptomic profiles in BCP-ALL that are associated with relapse, framing the discussion around five interconnected biological domains, namely cell death dysregulation and stress-adaptive survival; immune modulation and metabolic adaptation; developmental dysregulation and stemness; drug resistance; and post-transcriptional regulation. We focus specifically on transcriptomic signatures detectable at initial diagnosis, which reflect intrinsic leukemic cell states prior to therapeutic exposure, that may provide early indicators of relapse susceptibility. With the increasing availability of RNA-sequencing data across treatment centers, new opportunities are emerging to analyze these datasets beyond conventional subtype assignment. Comprehensive interrogation of transcriptomic profiles may help identify relapse-associated signatures that complement established clinical and genomic markers. As contemporary protocols continue to explore treatment de-intensification to minimize long-term toxicities, it is essential to ensure that patients classified as \u201clow-risk\u201d are accurately identified and do not harbor occult molecular features that predispose to relapse. This review provides a narrative overview of the transcriptomic determinants of relapse in BCP-ALL at diagnosis and highlights key knowledge gaps. By delineating the molecular pathways that may contribute to relapse, we aim to improve relapse prediction and provide a framework for future development of precise, personalized therapeutic strategies.<\/jats:p>","DOI":"10.3389\/fonc.2026.1778311","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:37:07Z","timestamp":1776227827000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Relapse in childhood B-cell precursor acute lymphoblastic leukemia: insights from transcriptomic signatures of diagnostic bone marrow"],"prefix":"10.3389","volume":"16","author":[{"given":"Lixian","family":"Oh","sequence":"first","affiliation":[{"name":"Department of Paediatrics, Faculty of Medicine, Universiti Malaya","place":["Kuala Lumpur, Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad Shafiq","family":"Azanan","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Faculty of Medicine, Universiti Malaya","place":["Kuala Lumpur, Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany","family":"Ariffin","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Faculty of Medicine, Universiti Malaya","place":["Kuala Lumpur, Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000069","article-title":"Advances in B-cell precursor acute lymphoblastic leukemia genomics","volume":"2","author":"Schwab","year":"2018","journal-title":"Hemasphere"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2025.1542649","article-title":"Analysis of global trends in acute lymphoblastic leukemia in children aged 0\u20135 years from 1990 to 2021","volume":"13","author":"Ding","year":"2025","journal-title":"Front Pediatr"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2018.78.3050","article-title":"Intensifying treatment of childhood B-lymphoblastic leukemia with IKZF1 deletion reduces relapse and improves overall survival: Results of Malaysia-Singapore ALL 2010 study","volume":"36","author":"Yeoh","year":"2018","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-016-0337-y","article-title":"Treatment of childhood acute lymphoblastic leukemia: Prognostic factors and clinical advances","volume":"11","author":"Vrooman","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003191","article-title":"A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia","volume":"135","author":"Enshaei","year":"2020","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)70243-8","article-title":"Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial","volume":"15","author":"Vora","year":"2014","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.01692","article-title":"Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude Total Therapy Study 16","volume":"37","author":"Jeha","year":"2019","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.64.6364","article-title":"Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: Study ALL10 from the Dutch Childhood Oncology Group","volume":"34","author":"Pieters","year":"2016","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.40.5936","article-title":"Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: Results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study","volume":"30","author":"Yeoh","year":"2012","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02347","article-title":"Anthracycline-free protocol for favorable-risk childhood ALL: A noninferiority comparison between Malaysia-Singapore ALL 2003 and ALL 2010 studies","volume":"41","author":"Ariffin","year":"2023","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.01086","article-title":"Outcome in children with standard-risk B-cell acute lymphoblastic leukemia: Results of Children's Oncology Group Trial AALL0331","volume":"38","author":"Maloney","year":"2020","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"5620","DOI":"10.1038\/s41598-025-86148-y","article-title":"Integrating bulk RNA-seq and scRNA-seq data to explore diverse cell death patterns and develop a programmed cell death-related relapse prediction model in pediatric B-ALL","volume":"15","author":"Luo","year":"2025","journal-title":"Sci Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-015-1982-6","article-title":"Overexpression of BCL2 and BAX following BFM induction therapy predicts ch-ALL patients' poor response to treatment and short-term relapse","volume":"141","author":"Stamati","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401866","article-title":"Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax\/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo","volume":"14","author":"Prokop","year":"2000","journal-title":"Leukemia"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2009.46","article-title":"Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy","volume":"16","author":"Laane","year":"2009","journal-title":"Cell Death Differ"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.193631","article-title":"Autophagy inhibition as a potential future targeted therapy for ETV6-RUNX1-driven B-cell precursor acute lymphoblastic leukemia","volume":"104","author":"Polak","year":"2019","journal-title":"Haematologica"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1186\/s12885-021-09076-w","article-title":"Identification of immune subtypes of Ph-neg B-ALL with ferroptosis related genes and the potential implementation of Sorafenib","volume":"21","author":"Hong","year":"2021","journal-title":"BMC Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41392-022-01046-3","article-title":"Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy","volume":"7","author":"Gao","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174495","article-title":"Neutrophil extracellular traps (NETs) in cancer invasion, evasion and metastasis","volume":"13","author":"Demkow","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.11064","article-title":"Prognostic significance of the tumor suppressor protein p53 gene in childhood acute lymphoblastic leukemia","volume":"19","author":"Weng","year":"2020","journal-title":"Oncol Lett"},{"key":"B21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12885-020-6599-8","article-title":"Expression of p53 N-terminal isoforms in B-cell precursor acute lymphoblastic leukemia and its correlation with clinicopathological profiles","volume":"20","author":"Oh","year":"2020","journal-title":"BMC Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1043111","article-title":"Integrating RNA-seq and scRNA-seq to explore the biological significance of NAD + metabolism-related genes in the initial diagnosis and relapse of childhood B-cell acute lymphoblastic leukemia","volume":"13","author":"Lin","year":"2022","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.872","article-title":"Gene expression prognostic of early relapse risk in low-risk B-cell acute lymphoblastic leukaemia in children","volume":"5","author":"Gong","year":"2024","journal-title":"EJHaem"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3186","article-title":"TIMD4 exhibits regulatory capability on the proliferation and apoptosis of diffuse large B-cell lymphoma cells via the Wnt\/beta-catenin pathway","volume":"22","author":"Li","year":"2020","journal-title":"J Gene Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05678-3","article-title":"TIM-4 orchestrates mitochondrial homeostasis to promote lung cancer progression via ANXA2\/PI3K\/AKT\/OPA1 axis","volume":"14","author":"Wang","year":"2023","journal-title":"Cell Death Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3892\/or.2018.6846","article-title":"Identification of biomarkers for the prediction of relapse-free survival in pediatric B-precursor acute lymphoblastic leukemia","volume":"41","author":"Jing","year":"2019","journal-title":"Oncol Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2182169","DOI":"10.21203\/rs.3.rs-963371\/v2","article-title":"PPARG, GNG12, and CD19 are potential independent predictors of central nerve recurrence in childhood acute lymphoblastic leukemia","volume":"28","author":"Zhang","year":"2023","journal-title":"Hematology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013733","article-title":"Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL","volume":"139","author":"Qi","year":"2022","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-218560","article-title":"Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia","volume":"115","author":"Kang","year":"2010","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.565455","article-title":"Identification of early recurrence factors in childhood and adolescent B-cell acute lymphoblastic leukemia based on integrated bioinformatics analysis","volume":"10","author":"Huang","year":"2020","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3221","article-title":"Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: Dominance of HOX dysregulation","volume":"102","author":"Ferrando","year":"2003","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/pin.12861","article-title":"Multiple functions of S100A10, an important cancer promoter","volume":"69","author":"Saiki","year":"2019","journal-title":"Pathol Int"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-002824","article-title":"Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: A Children's Oncology Group study","volume":"108","author":"Bhojwani","year":"2006","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01720-7","article-title":"Single-cell transcriptomics reveals a distinct developmental state of KMT2A-rearranged infant B-cell acute lymphoblastic leukemia","volume":"28","author":"Khabirova","year":"2022","journal-title":"Nat Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.186","article-title":"B4GALT family mediates the multidrug resistance of human leukemia cells by regulating the hedgehog pathway and the expression of p-glycoprotein and multidrug resistance-associated protein 1","volume":"4","author":"Zhou","year":"2013","journal-title":"Cell Death Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2009.01111.x","article-title":"Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells","volume":"100","author":"Kobune","year":"2009","journal-title":"Cancer Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3283","article-title":"NALP3 inflammasome up-regulation and CASP1 cleavage of the glucocorticoid receptor causes glucocorticoid resistance in leukemia cells","volume":"47","author":"Paugh","year":"2015","journal-title":"Nat Genet"},{"key":"B38","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41375-021-01341-y","article-title":"Identification and characterization of relapse-initiating cells in MLL-rearranged infant ALL by single-cell transcriptomics","volume":"36","author":"Candelli","year":"2022","journal-title":"Leukemia"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70176","article-title":"Ex vivo drug responses and molecular profiles of 597 pediatric acute lymphoblastic leukemia patients","volume":"9","author":"Enblad","year":"2025","journal-title":"Hemasphere"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2558","article-title":"Relapse specific mutations in NT5C2 in childhood acute lymphoblastic leukemia","volume":"45","author":"Julia","year":"2013","journal-title":"Nat Genet"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7604","article-title":"Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia","volume":"6","author":"Xiaotu","year":"2015","journal-title":"Nat Commun"},{"key":"B42","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1182\/blood.2019002220","article-title":"Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia","volume":"135","author":"Li","year":"2020","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2217\/epi-2019-0154","article-title":"miRNA deregulation in childhood acute lymphoblastic leukemia: A systematic review","volume":"12","author":"Gutierrez-Camino","year":"2020","journal-title":"Epigenomics"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/genes11030302","article-title":"Transcriptome analysis identifies LINC00152 as a biomarker of early relapse and mortality in acute lymphoblastic leukemia","volume":"11","author":"Barcenas-Lopez","year":"2020","journal-title":"Genes (Basel)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6692022","article-title":"Identification of a seven-lncRNA-mRNA signature for recurrence and prognostic prediction in relapsed acute lymphoblastic leukemia based on WGCNA and LASSO analyses","volume":"2021","author":"Qi","year":"2021","journal-title":"Anal Cell Pathol (Amst)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011583","article-title":"RNA-seq-based miRNA signature as an independent predictor of relapse in pediatric B-cell acute lymphoblastic leukemia","volume":"8","author":"Kubota","year":"2024","journal-title":"Blood Adv"},{"key":"B47","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40348-025-00210-3","article-title":"surviBALL: Exploring lncRNA expression at diagnosis for 5-year EFS risk stratification in pediatric B-ALL-a proof of concept","volume":"12","author":"Illarregi","year":"2025","journal-title":"Mol Cell Pediatr"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-18-1617","article-title":"Inhibition of Notch signaling enhances chemosensitivity in B-cell precursor acute lymphoblastic leukemia","volume":"79","author":"Takam Kamga","year":"2019","journal-title":"Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e41102","article-title":"Plasma-based transcriptomic non-coding signature for predicting relapse in pediatric acute lymphoblastic leukemia","volume":"10","author":"Wang","year":"2024","journal-title":"Heliyon"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v11.i2.268","article-title":"Allogeneic stem cell transplantation in the treatment of acute myeloid leukemia: An overview of obstacles and opportunities","volume":"11","author":"Yong-feng","year":"2023","journal-title":"World J Clin cases"},{"key":"B51","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1158\/0008-5472.bcd-19-0041","article-title":"Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia","volume":"1","author":"Waanders","year":"2020","journal-title":"Blood Cancer Discov"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-19-1059","article-title":"Relapse-fated latent diagnosis subclones in acute B lineage leukemia are drug tolerant and possess distinct metabolic programs","volume":"10","author":"Dobson","year":"2020","journal-title":"Cancer Discov"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02491-5","article-title":"Targeting LMO2-induced autocrine FLT3 signaling to overcome chemoresistance in early T-cell precursor acute lymphoblastic leukemia","volume":"39","author":"Tremblay","year":"2025","journal-title":"Leukemia"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1778311\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:37:23Z","timestamp":1776227843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1778311\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":53,"alternative-id":["10.3389\/fonc.2026.1778311"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1778311","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"article-number":"1778311"}}